vTv Therapeutics Inc. 5VT.F Stock
vTv Therapeutics Inc. Price Chart
vTv Therapeutics Inc. 5VT.F Financial and Trading Overview
vTv Therapeutics Inc. stock price | 0.28 EUR |
Previous Close | 0.67 EUR |
Open | 0.68 EUR |
Bid | 0.69 EUR x 120000 |
Ask | 0.71 EUR x 120000 |
Day's Range | 0.68 - 0.68 EUR |
52 Week Range | 0.61 - 1.32 EUR |
Volume | 100 EUR |
Avg. Volume | 6 EUR |
Market Cap | 55.41M EUR |
Beta (5Y Monthly) | -1.19507 |
PE Ratio (TTM) | N/A |
EPS (TTM) | 0 EUR |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
5VT.F Valuation Measures
Enterprise Value | 55.46M EUR |
Trailing P/E | N/A |
Forward P/E | -2.060606 |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | 3078.2693 |
Price/Book (mrq) | N/A |
Enterprise Value/Revenue | 3081.089 |
Enterprise Value/EBITDA | -2.371 |
Trading Information
vTv Therapeutics Inc. Stock Price History
Beta (5Y Monthly) | -1.19507 |
52-Week Change | 1.32% |
S&P500 52-Week Change | 20.43% |
52 Week High | 1.32 EUR |
52 Week Low | 0.61 EUR |
50-Day Moving Average | 0.73 EUR |
200-Day Moving Average | 0.81 EUR |
5VT.F Share Statistics
Avg. Volume (3 month) | 6 EUR |
Avg. Daily Volume (10-Days) | 0 EUR |
Shares Outstanding | 81.48M |
Float | 26.06M |
Short Ratio | N/A |
% Held by Insiders | 64.40% |
% Held by Institutions | 4.56% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | 0 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | 0% |
Operating Margin (ttm) | -130477.78% |
Gross Margin | 0% |
EBITDA Margin | 0% |
Management Effectiveness
Return on Assets (ttm) | -59.89% |
Return on Equity (ttm) | -641.21% |
Income Statement
Revenue (ttm) | 18K EUR |
Revenue Per Share (ttm) | 0 EUR |
Quarterly Revenue Growth (yoy) | N/A |
Gross Profit (ttm) | -9933000 EUR |
EBITDA | -23395000 EUR |
Net Income Avi to Common (ttm) | -16656000 EUR |
Diluted EPS (ttm) | -0.19 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 18.78M EUR |
Total Cash Per Share (mrq) | 0.23 EUR |
Total Debt (mrq) | 454K EUR |
Total Debt/Equity (mrq) | 111.28 EUR |
Current Ratio (mrq) | 2.418 |
Book Value Per Share (mrq) | -0.236 |
Cash Flow Statement
Operating Cash Flow (ttm) | -20167000 EUR |
Levered Free Cash Flow (ttm) | -18014500 EUR |
Profile of vTv Therapeutics Inc.
Country | Germany |
State | NC |
City | High Point |
Address | 3980 Premier Drive |
ZIP | 27265 |
Phone | 336 841 0300 |
Website | https://vtvtherapeutics.com |
Industry | Biotechnology |
Sector(s) | Healthcare |
Full Time Employees | 13 |
vTv Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on the development of orally administered treatments for diabetes. The company's lead drug candidate is TTP399, an orally administered, small molecule, and liver-selective glucokinase activator for the treatment of type 1 diabetes; and HPP737, an orally administered non-CNS penetrant phosphodiesterase type 4 (PDE4) inhibitor that addresses inflammatory diseases and psoriasis. It is also involved in the clinical development of other programs, including TTP273, an oral small molecule GLP-1 receptor agonist for postprandial glucose excursion to treat cystic fibrosis related diabetes; HPP3033, a non-electrophilic therapeutic approach to activating the Nrf2 pathway for the treatment of chronic diseases associated with oxidative stress; azeliragon, a RAGE antagonist for inflammatory lung diseases, including severe COVID-19, as well as for pancreatic and breast cancers; and HPP971, an Nrf2 activator. vTv Therapeutics Inc. has a license agreement with Reneo Pharmaceuticals, Inc. to develop and commercialize peroxisome proliferation activated receptor delta agonist program, including the compound HPP593; and license and research agreements with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.; Newsoara Biopharma Co., Ltd.; JDRF International; and Novo Nordisk A/S. The company was incorporated in 2015 and is headquartered in High Point, North Carolina. vTv Therapeutics Inc. is a subsidiary of MacAndrews & Forbes Incorporated.
Q&A For vTv Therapeutics Inc. Stock
What is a current 5VT.F stock price?
vTv Therapeutics Inc. 5VT.F stock price today per share is 0.28 EUR.
How to purchase vTv Therapeutics Inc. stock?
You can buy 5VT.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for vTv Therapeutics Inc.?
The stock symbol or ticker of vTv Therapeutics Inc. is 5VT.F.
Which industry does the vTv Therapeutics Inc. company belong to?
The vTv Therapeutics Inc. industry is Biotechnology.
How many shares does vTv Therapeutics Inc. have in circulation?
The max supply of vTv Therapeutics Inc. shares is 2.04M.
What is vTv Therapeutics Inc. Price to Earnings Ratio (PE Ratio)?
vTv Therapeutics Inc. PE Ratio is 0.00000000 now.
What was vTv Therapeutics Inc. earnings per share over the trailing 12 months (TTM)?
vTv Therapeutics Inc. EPS is 0 EUR over the trailing 12 months.
Which sector does the vTv Therapeutics Inc. company belong to?
The vTv Therapeutics Inc. sector is Healthcare.